Miltefosine

米替福新

Report date: 2026/05/22 20:01:29
NMEFirst In Class

Base Information

Drug NameMiltefosine
Drug Alias Namemiltefosinum米替福星灭特复星miltefosinaHexadecylphosphocholine +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSignal transduction pathway inhibitors
TargetsNot applicable
Therapy Area/IndicationsChronic UrticariaLeishmaniasis, VisceralLeishmaniasis, Mucocutaneous +[5] 
Global Approved IndicationsLeishmaniasis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2002/01/01
Country/TerritoryUnited StatesGermanyEthiopia +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesUniversidad Industrial De SantanderEton Pharmaceuticals IncInstitute Of Tropical Medicine Antwerp +[4] 
Inactive CompaniesUniversity Of AntioquiaCharite University, Berlin, GermanyAfter Bankruptcy Foundation Inc +[4] 
Active IndicationsLeishmaniasis, CutaneousLeishmaniasis
Inactive IndicationsChronic UrticariaLeishmaniasis, VisceralLeishmaniasis, Mucocutaneous

Other Information

ATC CodeP01CX04
Related LinksWikipediaDrugBankKEGG